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Aberrant accumulation of lipids in the liver (‘‘fatty
liver’’ or hepatic steatosis) represents a hallmark of
the metabolic syndrome and is tightly associated
with obesity, type II diabetes, starvation, or glucocor-
ticoid (GC) therapy. While fatty liver has been con-
nected with numerous abnormalities of liver function,
the molecular mechanisms of fatty liver development
remain largely enigmatic. Here we show that liver-
specific disruption of glucocorticoid receptor (GR)
action improves the steatotic phenotype in fatty liver
mouse models and leads to the induction of transcrip-
tional repressor hairy enhancer of split 1 (Hes1) gene
expression. The GR directly interferes with Hes1 pro-
moter activity, triggering the recruitment of histone
deacetylase (HDAC) activities to the Hes1 gene. Ge-
netic restoration of hepatic Hes1 levels in steatotic
animals normalizes hepatic triglyceride (TG) levels.
As glucocorticoid action is increased during starva-
tion, myotonic dystrophy, and Cushing’s syndrome,
the inhibition of Hes1 through the GR might explain
the fatty liver phenotype in these subjects.
INTRODUCTION
Triglycerides (TGs) represent the most efficient form of energy
storage in mammals. Under healthy conditions,uptake, synthesis,
and mobilization of TG in metabolic tissues are tightly controlled
by hormonal cues, in particular adrenal glucocorticoids (GCs)
(Gibbons et al., 2000). While storage of TG in adipose tissue is es-
sential for the maintenance of normal energy homeostasis, aber-
rant lipidaccumulation in peripheral tissues (suchas liverand skel-
etal muscle) is considered to be a key feature of severe metabolic
disorders (Saltiel, 2001). In particular, pathophysiological accu-212 Cell Metabolism 8, 212–223, September 3, 2008 ª2008 Elseviermulation of lipids in the liver has been identified as an independent
risk factor for insulin resistance and the metabolic syndrome
(Seppala-Lindroos et al., 2002), thereby promoting susceptibility
to severe end-stage diseases such as type II diabetes.
Chronically elevated GC levels have been tied to fatty liver de-
velopment, and as a result, may contribute to hepatic steatosis
(Andrews and Walker, 1999). Indeed, clinical studies have dem-
onstrated that GC levels are elevated in insulin-resistant and glu-
cose-intolerant patients (Phillips et al., 1998; Reynolds et al.,
2001). They are also associated with the fatty liver phenotype
in nonalcoholic fatty liver disease (NAFLD) (Targher et al.,
2006), myotonic dystrophy (Johansson et al., 2001), and so-
called metabolically obese, normal-weight subjects (Ruderman
et al., 1998). Moreover, fatty liver development also represents
a typical side effect of long-term systemic GC treatment during
anti-inflammatory therapy (Schacke et al., 2002), and hepatic
fat accumulation has been demonstrated in patients with Cush-
ing’s syndrome (Shibli-Rahhal et al., 2006). GC levels have been
shown consistently to be dramatically increased in various ani-
mal models of dyslipidemia and hepatic steatosis, such as the
db/db, ob/ob, and KKA(y) mouse (Anstee and Goldin, 2006).
At the cellular level, GCs mediate their physiologic effects
through binding to the glucocorticoid receptor (GR), a member
of the nuclear receptor superfamily of transcription factors.
Upon GC binding in the cytosol, the GR translocates into the
nucleus where it serves as a transcriptional regulator of distinct
GC-responsive target genes via direct DNA binding or through
protein-protein interactions with other transcriptional regulators
(Kassel and Herrlich, 2007). Whole-body GR-knockout mice
are not viable, demonstrating the importance of functional GR
action for survival (Cole et al., 1995). In liver, the GR has been
characterized as a critical regulator of glucose homeostasis, me-
diated—at least in part—through its direct recruitment to the
gene promoter region of key regulators of gluconeogenesis
(e.g., phosphoenolpyruvate carboxykinase [PEPCK]) (Stafford
et al., 2001), thereby contributing to the maintenance of blood
glucose levels during fasting (Opherk et al., 2004). However, inInc.
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cose homeostasis, the molecular role of the GR in hepatic lipid
metabolism remains largely unknown (Vegiopoulos and Herzig,
2007).
Based on the observed manifestation of dysfunctional hepatic
lipid homeostasis in pathologies with enhanced GC action and
tissue exposure, we hypothesized that in these settings, the
GR represents a critical transcriptional checkpoint for hepatic
steatosis.
RESULTS
Hepatic GR Deficiency Improves Hepatic Steatosis
in db/db Mice
To explore the role of the GR in hepatic lipid metabolism, we dis-
rupted the activity of the GR specifically in livers of db/db mice—
a standard model for hepatic steatosis and elevated GC levels
(Chen et al., 1996)—by delivering an adenovirus expressing
GR-specific shRNA via tail-vein injection.
GR shRNA treatment significantly inhibited GR mRNA levels
over a 21 day period with a maximum 10-fold reduction after 7
days as compared to nonspecific shRNA control littermates
(Figure 1A). At the day 7 time point, hepatic GR protein expres-
sion was found to be almost completely abolished (Figure 1B,
lanes 4–6 versus lanes 1–3), while GR expression in abdominal
white adipose tissue (WAT) and skeletal muscle (SkM) remained
unaffected (Figure 1B). In accordance with previous studies in
nonobese mice (Opherk et al., 2004), absence of hepatic GR in
the db/db animals caused a reduction in blood glucose levels un-
der both fasting and ad libitum conditions (see Figure S1A avail-
able online) and inhibited expression of gluconeogenic GR target
genes (Figure S1B), validating the experimental system.
Knockdown of GR expression in db/db livers caused a pro-
nounced decrease in hepatic TG levels throughout 14 days of
shRNA treatment (Figures 1C and 1D), returning to control values
with the restoration of hepatic GR protein expression after 21
days due to adenovirus clearance from the liver (data not shown).
Along with the reduction of hepatic TG stores, liver-specific GR
deficiency resulted in a decrease of total and very-low-density
lipoprotein (VLDL) serum TG levels at days 3 and 14 after virus
injection (Figures S1C and S1D), which was interrupted by a
transient increase of serum TG at day 7 (Figures S1C and
S1D), indicating that the GR regulates hepatic TG metabolism
and contributes to the steatotic phenotype in these animals.
Hepatic TG stores are determined by the relative balance of
lipid uptake and release, de novo TG formation (lipogenesis),
and fatty acid combustion via b-oxidation (Kersten et al.,
1999). Indeed, hepatic VLDL release, which is largely fed by in-
trahepatic TG stores (Gibbons et al., 2000), was significantly
reduced in GR-knockdown animals (Figure 1E). To determine
output from the fatty acid oxidation pathway, we measured cir-
culating levels of total ketone bodies in control and GR-depleted
animals. Consistent with lower hepatic TG content, mice defi-
cient in hepatic GR showed elevated levels of ketone bodies in
the serum throughout 14 days of GR shRNA treatment
(Figure 1F), indicating that disruption of GR expression reduces
steatosis in db/db animals partly by triggering hepatic fatty acid
oxidation and ketogenesis.Cell MThe maximum reduction of GR expression at day 7 caused no
differences in serum insulin levels (Figure S2A), body weight
(Figure S2B), skeletal muscle TG content (Figure S2C), abdomi-
nal fat pad mass (Figure S2D), circulating nonesterified fatty
acids (NEFA) (Figure S2E), total body-fat content (Figure S2F),
and hepatic macrophage infiltration (Figure 1D), as compared
to controls. These data argue against a role for contributions
from extrahepatic tissues or inflammatory reactions on the ob-
served lipid phenotypes. Circulating corticosterone levels were
elevated 2-fold in animals lacking hepatic GR expression
(Figure S2G), likely reflecting a compensatory mechanism in re-
sponse to the ablation of hepatic GC/GR signaling.
We next sought to determine the molecular basis for the ob-
served phenotypic changes in GR-deficient db/db mice by
quantitative PCR analysis of key regulatory genes involved in
hepatic lipid metabolism. Except for an inhibition of PPARg
(Yu et al., 2003), loss of GR had no significant effects on lipogenic
gene expression (Figure 2A) or enzyme activity (e.g., acetyl-
CoA carboxylase [ACC] 1 Ser79 phosphorylation, data not
shown), but reduced the hepatic expression of genes critical
for lipid storage and transport such as caveolin (CAV) (Fernandez
et al., 2006), fatty acid transporter CD36 (Coburn et al., 2001),
and microsomal TG transfer protein (MTTP) (Gibbons et al.,
2000), compared to controls (Figure 2B). Consistent with the el-
evation of total serum ketone bodies (Figure 1F), expression
of genes in the fatty acid oxidation pathway such as carnitine
palmitoyltransferase (CPT) 1a and acetyl-CoA acyltransferase
(ACAA) 2 (Hu et al., 2005) were significantly increased in GR-de-
ficient livers, while a critical inhibitor of fatty acid oxidation, ace-
tyl-CoA carboxylase beta (ACACB) (Abu-Elheiga et al., 2001),
was inhibited more than 2-fold when compared to controls
(Figure 2C). Unexpectedly, GR knockdown also promoted the
de novo induction of pancreatic lipase (PNL) mRNA from unde-
tectable levels and resulted in a 4-fold induction of pancreatic li-
pase-related protein (PNLRP) 2 mRNA expression (Figure 2D).
These lipases are normally only present at low levels in the liver
and may promote hepatic TG hydrolysis and ketogenesis (Ina-
gaki et al., 2007).
Further analysis revealed that expression of the cholestero-
genic transcription factor sterol regulatory element binding pro-
tein (SREBP) 2 was elevated upon GR knockdown (Figure 2E),
while cholesterol and bile acid transporter expression was signif-
icantly diminished in these animals (Figure 2E). Indeed, maxi-
mum GR knockdown after 7 and 14 days caused intrahepatic
cholesterol accumulation (Figure S3A), while at the same time
triggering a reduction of total and low/high-density lipoprotein
(LDL/HDL) serum cholesterol levels (Figures S3B and S3C).
These results suggest that the loss of GR function in db/db
livers ameliorates hepatic steatosis in these mice by specifically
triggering the hydrolysis of TG stores and their usage in the fatty
acid oxidation pathway and simultaneously leads to the retention
of hepatic cholesterol.
Transcriptional Repressor Hes1 Is a Negative
GR Target Gene
In additional gene profiling studies, we noticed that mRNA levels
for cAMP-inducible transcriptional repressor Hes1 (Herzig et al.,
2003) were strongly induced over controls in livers of GR shRNA-
treated db/db mice (Figure 3A), which was confirmed at proteinetabolism 8, 212–223, September 3, 2008 ª2008 Elsevier Inc. 213
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expression of other Hes family members was not changed upon
GR depletion (Figure S4A), suggesting a specific inhibitory im-
pact of the GR on Hes1.
To test this conclusion in an independent setting, C57Bl6 mice
were treated with the GC analog dexamethasone (DEX) or saline
for 3 weeks, and liver extracts were analyzed by quantitative
PCR and western blot. DEX-mediated activation of the GR re-
sulted in a dramatic reduction of hepatic Hes1 mRNA (Figure 3C)
and protein (Figure 3D, lanes 5–8 versus lanes 1–4) levels, and
substantially increased hepatic TG (Figure S4B). Identical results
were obtained by treating primary mouse hepatocytes with DEX
(Figure 3E), demonstrating the cell autonomy of this effect.
The inhibitory effect of the GR on Hes1 in db/db mice promp-
ted us to investigate the general importance of this regulation in
fatty liver models. To this end, we analyzed liver extracts from
Figure 1. Knockdown of Hepatic GR
Results in Altered Lipid Homeostasis in
db/db Mice
(A) Quantitative PCR analysis of GR mRNA levels
in livers of control (Ctrl) or GR shRNA adenovi-
rus-injected db/db mice various time points after
injection as indicated (means ± SEM, n = 5).
(B) Western blot of liver, abdominal white adipose
tissue (WAT), and gastrocnemius muscle (SkM)
extracts from three representative controls (Ctrl,
lanes 1–3) or GR (lanes 4–6) shRNA adenovirus-in-
jected db/db mice 7 days after injection using GR
antibody.
(C) Liver TG levels in same mice as in (A) (means ±
SEM, n = 5).
(D) Liver sections from Ctrl or GR shRNA adenovi-
rus-injected db/db mouse 7 days after injection
stained with hematoxylin and eosin (H&E), Oil
Red O, or the macrophage marker F4/80. The un-
stained vacuoles visible in the H&E sections of the
GR-knockdown mice stain positive (red color) for
lipids with Oil Red O.
(E) Hepatic VLDL release in control or GR shRNA
adenovirus-injected db/db mice. Time after tylox-
apol injection is indicated (means ± SEM, n = 6).
(F) Serum total ketone body levels in same mice as
in (A) (means ± SEM, n = 5). The * indicates signif-
icance.
healthy db/+ or New Zealand Black
(NZB) mice compared to db/db and
New Zealand Obese (NZO) mice, respec-
tively, the latter representing a multigenic
diabetes model (Leiter and Reifsnyder,
2004). Correlating with the steatotic phe-
notype in both models, Hes1 protein ex-
pression was found to be diminished
1.6- and 3-fold in these animals when
compared to corresponding controls
(Figures 3F and 3G, lanes 4–6 versus
lanes 1–3, respectively; Figures S4C
and S4D).
In contrast to the chronic steatosis in
db/db and NZO models, long-term star-
vation has been shown to acutely induce a fatty liver phenotype
(Kersten et al., 1999) and is associated with increased GC levels
(Opherk et al., 2004). After 48 hr starvation, Hes1 mRNA levels
declined significantly when compared to fed controls
(Figure 3H). In contrast, in mice carrying a liver-specific disrup-
tion of the GR gene (GRKO) (Opherk et al., 2004), starvation for
48 hr did not cause an inhibition of Hes1 expression in liver,
whereas Hes1 levels were substantially diminished in control lit-
termates (Figure 3H). Notably, in GRKO mice, sustained Hes1
expression was associated with the prevention of starvation-in-
duced hepatic TG accumulation (Figure S4E).
Additional kinetic experiments in C57Bl6 mice revealed that
Hes1 gene expression was not inhibited 6 hr after food depriva-
tion but was reduced after 24 hr of starvation, an effect that was
maintained throughout the 48 hr time point (Figure S4F). These
effects went along with the starvation-induced accumulation of214 Cell Metabolism 8, 212–223, September 3, 2008 ª2008 Elsevier Inc.
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is not a simple consequence of liver steatosis per se.
Taken together, these experiments demonstrate that a de-
creased hepatic Hes1 expression is a common feature of various
fatty liver paradigms and provide genetic evidence that GR func-
tion is required for the inhibition of Hes1.
The GR-Hes1 Regulatory Axis Controls Distinct Aspects
of Hepatic TG Metabolism
To establish the functional link between Hes1 deficiency and
GR-dependent fatty liver phenotype, we performed genetic re-
constitution experiments in db/db mice characterized by low-
level Hes1 expression as shown above (Figure 3F). Adenovi-
rus-mediated overexpression of Hes1 in livers of db/db mice
Figure 2. Hepatic GR Controls Genes in the
Fatty Acid Oxidation and Lipolytic Pathway
(A) Quantitative PCR analysis of (A) lipogenic
(PPARg, LXR, ACC1, and SREBP-1c).
(B) TG storage and uptake (CAV, CD36, MTTP,
and ApoB).
(C) Fatty acid oxidation (PPARa, CPT1a, ACCA2,
and ACACB).
(D) Lipolytic (CEL, PNL, and PNLRP2) and (E) cho-
lesterogenic/bile acid (BA) (SREBP-2, ABCG1,
ABCA1, ABCG5, BSEP, and CYP7A1) gene
mRNA levels in livers of Ctrl or GR shRNA adeno-
virus-injected db/db mice 7 days after injection
(means ± SEM, n = 5). ND indicates nondetect-
able, and * indicates significance.
(Figure S5A, lanes 5–8 versus lanes 1–4)
substantially lowered hepatic TG levels
when compared to littermates infected
with a GFP-control adenovirus (Figure 4A,
left). In contrast, hepatic cholesterol levels
remained unaffected (Figure 4A, right), ar-
guing that Hes1 specifically regulates TG
metabolism. Expression analysis in these
mice revealed that key regulatory en-
zymes in the TG uptake and storage
pathway (e.g., CAV, CD36, PPARg, and
fat-specific protein [FSP27]) were signifi-
cantly downregulated when compared
to controls (Figure S5C). In addition, over-
expression of Hes1 triggered the de novo
appearance ofPNLmRNA and stimulated
PNLRP2mRNA levels by 2.5-fold as com-
pared to control mice (Figure 4B), thereby
recapitulating the induction of lipase gene
expression in GR-deficient db/db livers
(Figure 2D). Accordingly, Hes1 reconstitu-
tion in db/db mice did not significantly
affect other Hes family members
(Figure S5B) as well as genes related to
lipogenesis, gluconeogenesis, or choles-
terol synthesis, includingperoxisomepro-
liferator-activated receptor coactivator
(PGC)-1a, ACC1, fatty acid synthase
(FAS), SREBP-1c, liver X receptor (LXR), SREBP-2, and ATP-
binding cassette (ABC) transporters G1/A1 (Figure S5C). To test
whether Hes1 can induce these phenotypes in a cell-autono-
mous manner, we infected primary mouse hepatocytes with the
Hes1-overexpressing adenovirus (Figure S5D). While cellular
cholesterol levels remained unchanged (Figure 4C, right), induc-
tion of Hes1 protein expression led to a marked decrease in cel-
lular TG levels and promoted PNLRP2 and PNL mRNA expres-
sion 7- and 21-fold, respectively (Figures 4C [left] and 4D). The
combined data from db/db mice and primary hepatocytes indi-
cate that Hes1 indeed represents a transcriptional checkpoint
for hepatic TG metabolism.
DEX and other GCs have been used clinically for decades, and
long-term treatment is commonly associated with metabolicCell Metabolism 8, 212–223, September 3, 2008 ª2008 Elsevier Inc. 215
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(A) Quantitative PCR analysis of Hes1 mRNA levels in livers of Ctrl or GR shRNA adenovirus-injected db/db mice 7 days after injection (means ± SEM, n = 5).
(B) Western blot of liver extracts from three representative controls (Ctrl) or GR shRNA adenovirus-injected db/db mice using Hes1 or VCP antibodies.
(C) Quantitative PCR analysisofHes1mRNA levels in livers of C57Bl6 mice treated withDEX (1mg/kg/day) or saline (Ctrl) for a period of 3 weeks (means ± SEM,n = 7).
(D) Western blot of liver extracts from four representative animals treated as in (C) using Hes1 and VCP antibodies.
(E) Representative western blot of cell extracts from primary mouse hepatocytes treated with DEX (10 nM) or saline for 3 hr as indicated using Hes1 and VCP
antibodies (n = 6).
(F and G) Western blot of liver extracts from three representative db/+ (lanes 1–3) or db/db (lanes 4–6) mice using Hes1 or VCP antibodies. Comparison of New
Zealand Black (NZB) and New Zealand Obese (NZO) animals is shown in (G). Relative amounts of Hes1 (quantitative) were normalized to VCP protein levels.
(H) Quantitative PCR analysis ofHes1mRNA levels in livers of fed or 48 hr starved control (wt) or liver-specificGR-knockout mice (GRKO) (means ± SEM, n = 5). The *
indicates significance.side effects such as hyperglycemia, and in particular, hepatic
steatosis (Vegiopoulos and Herzig, 2007). To finally test whether
the inhibition of Hes1 through the GR can account for these216 Cell Metabolism 8, 212–223, September 3, 2008 ª2008 Elseviereffects, C57Bl6 mice were treated with DEX or saline for a total
of 3 weeks. After 2 weeks of DEX or saline treatment, mice
were additionally injected with Hes1-overexpressing or controlInc.
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(A) Liver TG (left) and cholesterol (Chol, right) levels in db/db mice injected with GFP control (Ctrl) or Hes1-overexpressing adenovirus (means ± SEM, n = 5).
(B) Quantitative PCR analysis of lipase (PNL, PNLRP2) gene mRNA levels in same mice as in (A) (means ± SEM, n = 5).
(C) TG (left) and cholesterol (Chol, right) levels in primary mouse hepatocytes infected with GFP control (Ctrl) or Hes1-overexpressing adenovirus for 48 hr
(means ± SEM, n = 9).
(D) Quantitative PCR analysis of lipase (PNL, PNLRP2) gene mRNA levels in same cells as in (C) (means ± SEM, n = 9). The * indicates significance.adenovirus, respectively. As shown above (Figure 3D), DEX-me-
diated activation of the GR resulted in a dramatic reduction of en-
dogenous hepatic Hes1 protein levels (Figure 5A, lanes 3 and 4
versus lanes 1 and 2), which were completely rescued by the
Hes1 adenovirus to physiological levels (Figure 5A, compare
lanes 3 and 4 versus lanes 7 and 8). Reintroduction of Hes1
did not affect GR protein levels in liver, WAT, or skeletal muscle
(data not shown). Consistent with previous reports (Opherk et al.,
2004), DEX treatment led to the induction of gluconeogenic gene
expression in the liver (data not shown), but failed to induce hy-
perglycemia (Figure S6A), most likely due to a compensatory in-
crease in serum insulin levels (Figure S6B). DEX exposure did not
affect body weight (Figure S6C) and skeletal muscle TG content
(Figure S6D) as compared to controls, but in accordance with the
lipolytic activity of GCs (Vegiopoulos and Herzig, 2007), de-
creased abdominal fat pad mass (Figure S6E) and elevated se-
rum NEFA levels (Figure S6F). As shown previously (Qi et al.,
2004), DEX acutely decreased serum VLDL TG levels (Figures
S7A and S7B), but had no significant effect on total and HDL
cholesterol (Figures S7C and S7D).
Hes1 rescue in DEX-treated animals completely abolished the
induction of hepatic TG accumulation when compared to mice
receiving control adenovirus (Figure 5B) and induced serum total
ketone body levels by 2-fold under basal and DEX-treated condi-Cell Mtions (Figure 5C). No significant effect of Hes1 reconstitution in
DEX-treated animals could be detected on hepatic cholesterol
levels (Figure S6G), again indicating that the GR/Hes1 axis spe-
cifically controls hepatic TG metabolism. Indeed, DEX treatment
resulted in a 3- to 5-fold inhibition of PNL and PNLRP2 mRNA
levels, respectively, whereas Hes1 reconstitution led to a 2- to
3-fold rescue of lipase gene expression in DEX-treated animals
(Figure 5D). In contrast, no significant effect of Hes1 rescue on
gluconeogenic, lipogenic, or cholesterogenic genes could be ob-
served under control or DEX-treated conditions (data not shown).
Together, these data support the notion that under conditions
of elevated GC action, the GR plays a key role in enhancing he-
patic TG accumulation through the repression of Hes1, which, in
turn, specifically blocks hepatic (de novo) induction of pancreatic
lipase gene expression.
GR Controls Hes1 Gene Expression through Direct
Promoter-Associated Mechanisms
The identification of Hes1 as a negative GR target gene promp-
ted us to finally explore the molecular basis for this regulation. In
chromatin coimmunoprecipitation (ChIP) studies using liver ex-
tracts from starved or fed C57Bl6 mice, the Hes1 promoter
was efficiently recovered from immunoprecipitates of GR but
not of control IgG (Figure 6A), indicating that Hes1 representsetabolism 8, 212–223, September 3, 2008 ª2008 Elsevier Inc. 217
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(A) Western blot of liver extracts from two representative control GFP- (Ctrl, lanes 1–4) or Hes1- (lanes 5–8) injected C57Bl6 mice using Hes1 or VCP antibodies.
Animals were treated with saline (lanes 1–2 and lanes 5–6) or DEX (1 mg/kg/day) (lanes 3–4 and lanes 7–8) for 3 weeks and analyzed 3 hr after the final DEX
injection.
(B) Liver TG levels in same animals as in (A) (means ± SEM, n = 7).
(C) Total ketone body levels in same animals as in (A) (means ± SEM, n = 7).
(D) Quantitative PCR analysis of lipase (PNL, PNLRP2) gene mRNA levels in same mice as in (A) (means ± SEM, n = 7). The * indicates significance.a direct GR target gene in vivo. Consistently, in affinity selection
assays using oligos harboring GR consensus (GRE) (Figure 6B,
lane 7), random negative control (Figure 6B, lane 6), or various
Hes1 proximal promoter fragments (Figure 6B, lanes 1–5), re-
spectively, GR was found to associate with high affinity to
a Hes1 promoter sequence between 463 and 414 bp up-
stream of the transcription start site, which carries a consensus
half site for GR binding (TGTTCC) (Morin et al., 2000). Indeed, de-
letion of this site completely abolished the inhibitory effect of
DEX on Hes1 promoter activity in transient transfection assays
(Figure 6C), demonstrating that the GR functionally impairs
Hes1 gene expression through promoter site-dependent effects.
To this end, transient transfection of either wild-type GR or DNA
binding-deficient mutants (GR dim and GR D4X, Heck et al.
[1994]) in HEK293 cells demonstrated that only wild-type GR
was able to restore DEX responsiveness of these cells and to218 Cell Metabolism 8, 212–223, September 3, 2008 ª2008 Elsevierinhibit Hes1 promoter activity (Figure 6D), supporting the notion
that GR DNA binding is required for the inhibitory effect on
Hes1 promoter function. Negative regulation of gene transcrip-
tion by the GR has been partly attributed to the recruitment of
histone deacetylase (HDAC) activities to corresponding target
gene promoters (Kassel and Herrlich, 2007). Consistent with
this observation, treatment of H4IIE hepatocytes with the
HDAC class I and class II inhibitor trichostatin A (TSA) abolished
the DEX-mediated repression of Hes1 protein expression
(Figure 6E, lane 2 versus 4) and prevented the inhibition of
Hes1 promoter activity by DEX (Figure 6C). These data suggest
that the GR recruits cellular HDAC activities to the Hes1 pro-
moter, thereby conferring transcriptional repression in response
to GC signaling. To test this hypothesis directly, we finally per-
formed ChIP experiments using HDAC-specific antibodies.
DEX treatment of cultured liver cells triggered the recruitmentInc.
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Glucocorticoid Receptor Represses Hes1Figure 6. Hes1 Represents a Direct Negative Transcriptional Target of the GR
(A) Representative ChIP assay of Hes1 promoter in livers of starved (48 hr) or fed C57Bl6 mice as indicated using GR or IgG control antibody.
(B) ABCD binding assay using cell extracts from H4IIE hepatocytes and biotinylated oligonucleotides comprising distinct Hes1 promoter or GRE consensus
sequences. Bound proteins were detected by western blot analysis using a GR-specific antibody (random, negative control; Lane 8, 10% input).
(C) Transient transfection assay of H4IIE hepatocytes cotransfected withHes1 luciferase reporter463 or414 as indicated. Cells were treated with DEX (10 nM),
trichostatin A (TSA) (100 ng/ml), or left untreated as indicated (means ± SEM, n = 9).
(D) Transient transfection assay of HEK293 cells cotransfected with Hes1 luciferase reporter463 and expression constructs for wild-type GR (wt), or DNA bind-
ing-deficient mutants (GR dim, GR D4x) as indicated. Cells were treated with DEX (10 nM) for 24 hr or left untreated (Ctrl) (means ± SEM, n = 9).
(E) Representative western blot of H4IIE liver cells treated with DEX (10 nM) and/or trichostatin A (TSA) (100 ng/ml) as indicated using Hes1 or VCP antibodies.
(F) Representative ChIP assay of Hes1 promoter in H4IIE cells treated with DEX (10 nM) for 3 hr as indicated using specific antibodies against HDAC1, acetylated
histone H3, p300, or nonspecific IgG. The * indicates significance.of HDAC1 to the Hes1 promoter (Figure 6F), but not of HDAC2 or
3 (data not shown). Consistent with an inhibition of Hes1 gene
transcription, DEX exposure also abolished histone H3 promoter
acetylation, a marker of actively transcribed genes (Figure 6F,
ac-histone H3) and released binding of acetyltransferase coacti-
vator p300 from the Hes1 promoter (Figure 6F, p300).
These results demonstrate that the GR interferes with Hes1
expression through direct promoter association in vivo, at leastCell Min part, by triggering the recruitment of cellular HDAC activity
and the simultaneous disassembly of transcriptional coactivator
complexes.
DISCUSSION
Hepatic steatosis has been identified as a common hallmark of
numerous pathologies, including NAFLD, Cushing’s syndrome,etabolism 8, 212–223, September 3, 2008 ª2008 Elsevier Inc. 219
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Glucocorticoid Receptor Represses Hes1obesity, and the metabolic syndrome (Kersten et al., 1999; Saltiel,
2001).Despite the common feature of hepaticsteatosis, these con-
ditions differquite substantially in theirhormonal regimens.Obesity
and the metabolic syndrome are associated with normal or even
low GC tone (Macfarlane et al., 2008). Along with starvation, myo-
tonic dystrophy and Cushing’s syndrome represent in contrast
a subset of diseases characterized by elevated systemic and/or
local GC levels, accompanied by fatty liver development, hypergly-
cemia, and insulin resistance (Vegiopoulos and Herzig, 2007).
Numerous studies have demonstrated the importance of the
GC/GR pathway in the control of hyperglycemia (Opherk et al.,
2004). Our acute GR-knockdown model now points to a critical
role of the GC/GR pathway for the manifestation of hepatic stea-
tosis. These findings are consistent with a previous study show-
ing that the GR promotes transient hepatocellular fat accumula-
tion following partial hepatectomy (Shteyer et al., 2004). Our
results suggest that the promotion of hepatic TG accumulation
through the GR relies on the combinatorial inhibition of fatty
acid and TG uptake and storage, fatty acid oxidation, and the
prevention of pancreatic lipase activities. Indeed, recent studies
have suggested that the de novo expression of pancreatic li-
pases in liver importantly contributes to TG hydrolysis and the
subsequent stimulation of fatty acid oxidation and ketogenesis
(Inagaki et al., 2007). Therefore, the GR seems to trigger hepatic
TG accumulation through a bipartite mechanism, compromising
the fatty acid supply for oxidation and simultaneously inhibiting
key enzyme gene expression in the latter pathway. These effects
are likely to foster the re-esterification of fatty acids to TG (Baar
et al., 2005), thereby providing an additional indirect trigger for
GR-mediated TG buildup, which may translate into elevated
serum VLDL TG levels (Figure S1D).
Essential components that mediate the TG-regulating proper-
ties of the GR appear to stem from the inhibition of Hes1, identi-
fied here as a negative target gene of GC/GR signaling. In fact,
Hes1 reconstitution in DEX-treated animals was found to be suf-
ficient to reverse GC-induced hepatic TG accumulation (Figure 5).
Interestingly, Hes1 seems to predominantly control the ‘‘lipase
arm’’ of GR-dependent TG metabolism as the most significant
transcriptional effects of Hes1 were found to be related to PNL
and PNLRP2 gene expression (Figures 4 and 5). It is tempting
to speculate that the inhibition of Hes1 by the GR in fatty liver
mouse models represents a key mechanism in the prevention
of lipase activities, thereby promoting TG accumulation under
these conditions. In support of this hypothesis, hepatic PNL
and PNLRP2mRNA levels tended to be higher in healthy animals
as compared to steatotic mice (unpublished data), thereby asso-
ciating with the increased Hes1 expression in the former animals.
The effects of hepatic GR on cholesterol metabolism seem to
be independent of Hes1. Neither Hes1 reconstitution in db/db or
DEX-treated animals affected cholesterol lipid parameters or cho-
lesterogenic gene expression (Figures 4, 5, and S5). However, rel-
atively small alterations in GR-expression levels led to significant
cholesterol phenotypes. It will be interesting to determine whether
these effects are mediated through the observed regulation of
SREBP-2 or reflect a direct regulatory role of the GR on genes in-
volved in cholesterol/bile acid biosynthesis and/or transport.
As discussed above, the GR/Hes1 pathway is likely causative
for the fatty liver development in a subset of GC-driven patholo-
gies. Hepatic steatosis under conditions of normal or even low220 Cell Metabolism 8, 212–223, September 3, 2008 ª2008 ElsevieGC levels, as frequently found in obese humans (Macfarlane
et al., 2008), is presumably controlled by different regulators in-
cluding the SREBP-1c (Shimomura et al., 1998) and PPARg
transcriptional pathways (Matsusue et al., 2008). However, it re-
mains to be determined whether or how these factors intertwine
with the GR/Hes1 cascade. At the level of gene expression, GR/
Hes1 tended to increase SREBP-1c expression (although statis-
tically not significant), whereas PPARg and its downstream tar-
get FSP27 were found to be inhibited by GR deficiency and/or
Hes1 overexpression. Since PPARg has been shown to drive he-
patic lipid accumulation through FSP27 (Matsusue et al., 2008)
and is a direct Hes1 target gene (Herzig et al., 2003), it is conceiv-
able that specific downstream effects of the GR/Hes1 axis are
mediated by this transcription factor. PPARg might, thereby,
represent a point of convergence for GC-dependent and -inde-
pendent fatty liver disease.
The regulation of Hes1 gene expression has been mainly inves-
tigated in the context of Notch-dependent cellular differentiation
and proliferation (Iso et al., 2003). In addition, our own previous
work had identified Hes1 as a cAMP/CREB target gene in the
liver, harboring a classical CRE at position215 bp from the tran-
scription start site (Herzig et al., 2003). The current study now
suggests that in contrast to the stimulatory effect of the cAMP
pathway, GC promote Hes1 gene repression through the GR. In
contrast to gluconeogenic gene expression, which is synergisti-
cally triggered by cAMP and GC (Herzig et al., 2001), Hes1 seems
to represent a subclass of common cAMP/GR targets that is
antagonistically regulated by both pathways. Prototypical
examples of these targets are hypothalamic genes within the
hypothalamic-pituitary axis (HPA)/GC-feedback loop, such as
corticotrophin-releasing hormone (CRH) (Yamamori et al., 2007).
In contrast to CRH, GR inhibits both cAMP-activated and basal
Hes1 gene expression, independent of the CRE and in an
HDAC-dependent manner and without obvious direct physical
interference with CREB activity (unpublished data). It will be inter-
esting to investigate the exact promoter arrangements responsi-
ble for synergistic or antagonistic gene regulatory functions of
cAMP and GC pathways, given the importance of both hormonal
circuits for systemic energy homeostasis. In this respect, one
might speculate that cAMP-inducing agonists, such as glucagon
or glucagon-like-peptide (GLP)-1, could provide therapeutic ben-
efit in GC/GR-driven hepatic lipid pathologies by maintaining
Hes1 expression. Indeed, the cAMP pathway has been shown
to prevent hepatic lipid accumulation in mice (Herzig et al.,
2003), and elevation of intrahepatic cAMP levels through GLP-1
mimetics have been demonstrated to ameliorate hepatic steato-
sis in mice and humans (Ding et al., 2006; Tushuizen et al., 2006).
Taken together, our studies identify a metabolic axis compris-
ing GR nuclear receptor and Hes1 repressor components. The
ability of the GR to control hepatic lipid accumulation by interfer-
ing with the expression of Hes1 indicates that the GR/Hes1




Adenoviruses expressing Hes1 or control GFP only and adenoviruses ex-
pressing GR-specific or nonspecific shRNA under control of the U6 promoterr Inc.
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Viruses were purified by the cesium chloride method and dialyzed against
phosphate buffer containing 10% glycerol prior to animal injection.
Animal Experiments
Male 8- to 12-week-old C57Bl6, db/db, db/+, and New Zealand Obese (NZO)/
New Zealand Black (NZB) mice were obtained from Charles River Laboratories
(Brussels, Belgium) and maintained on a 12 hr light-dark cycle with regular un-
restricted diet. For starvation experiments, animals were fasted for 6 hr, 24 hr,
or 48 hr with free access to water or fed ad libitum. In separate experiments,
male 8-week-old C57Bl6 mice received daily intraperitoneal injections of
DEX (1 mg/kg body weight) or saline for 3 weeks and were analyzed 3 hr after
the final DEX injection. For virus injections, 1–33 109 plaque-forming units per
recombinant virus were administered via tail-vein injection. In each experi-
ment, five to seven animals received identical treatments and were analyzed
under ad libitum fed conditions, unless stated otherwise. Organs including
liver, epididymal fat pads, and gastrocnemius muscles were collected after
the corresponding time periods, weighed, snap-frozen, and used for further
analysis. Studies with GR-knockout mice carrying a targeted disruption of
the GR gene (Opherk et al., 2004) were performed as described above. Total
body fat content was determined by an Echo MRI body-composition analyzer
(Echo Medical Systems, Houston, TX). Animal handling and experimentation
were done in accordance with NIH guidelines and approved by local authori-
ties.
Blood Metabolites
Serum levels of glucose, corticosterone, insulin, TG, cholesterol, total ketone
bodies, and NEFA were determined by using an automatic glucose monitor
(One Touch, Lifescan, Neckargemu¨nd, Germany) or commercial kits (MP
Biomedicals, Orangeburg, NY; Mercodia, Uppsala, Sweden; Sigma, Munich,
Germany; RANDOX, Crumlin, UK; WAKO, Neuss, Germany).
Hepatic VLDL Release
VLDL production was determined after tyloxapol (SIGMA, Munich, Germany)
injection as described (Mandard et al., 2006).
Fast Protein Liquid Chromatography (FPLC)
Serum from five to seven mice per experimental group was pooled and sub-
jected to FPLC as previously described (Lichtenstein et al., 2007). Cholesterol
and TG were measured in the eluted fractions using commercial kits as above.
Tissue Lipid Extraction
Hepatic and gastrocnemius skeletal muscle lipids were extracted as described
previously (Herzig et al., 2003), and TG and total cholesterol content were de-
termined using commercial kits as above. Values were calculated as micro-
mole (TG) or mg (cholesterol) per gram of wet tissue.
Quantitative Taqman RT-PCR
Total RNA was extracted from homogenized mouse liver or cell lysates using
the RNeasy Kit (QIAGEN, Hilden, Germany). cDNA was prepared by reverse
transcription using the M-MuLV enzyme and Oligo dT primer (Fermentas, St.
Leon-Rot, Germany). cDNAs were amplified using Assay-On-Demand Kits
and an ABIPRISM 7700 Sequence Detector (Applied Biosystems, Darmstadt,
Germany). RNA expression data was normalized to levels of TATA-box binding
protein (TBP) RNA.
Protein Analysis
Protein was extracted from frozen organ samples or cultured hepatocytes in
cell lysis buffer, and 20 mg of protein were loaded onto a 10% SDS-polyacryl-
amide gel and blotted onto nitrocellulose membrane. Western blot assays
were performed as described (Herzig et al., 2001) using antibodies specific
for Hes1 (Ito et al., 2000), phospho-Ser79 ACC1, GR, CREB (Santa Cruz, Hei-
delberg, Germany), or valosin-containing protein (VCP) (Abcam, Cambridge,
UK).
Histochemistry and Immunohistochemistry
Liver tissue was fixed in 4% paraformaldehyde for 24 hr and paraffin embed-
ded. Five micromolar sections were stained with hematoxylin/eosin (H&E). ForCell MOil Red O lipid staining, 5 mm cryosections of liver embedded in Tissue Tek
OCT compound (Sakura, NL) were fixed in Baker’s formol. Immunostaining
of macrophages was performed on acetone-fixed cryosections by a rat anti-
mouse F4/80 antibody (Serotec, Du¨sseldorf, Germany; 1: 100) and Cy3-conju-
gated anti-rat IgG (Dianova, Hamburg, Germany; 1: 200). Nuclei were counter-
stained with either hematoxylin or Hoechst-dye.
ChIP Assay
Rat H4IIE hepatocytes or homogenized mouse liver lysates were fixed with
formaldehyde, and ChIP assays were performed as described (Canettieri
et al., 2003) using antibodies specific for acetylated histone H3 (Upstate,
Lake Placid, NY), HDAC1, HDAC2, HDAC3, GR, p300, or unspecific IgG (Santa
Cruz, Heidelberg, Germany). Precipitated DNA fragments were analyzed by
PCR amplification using primers directed against the Hes1 promoter.
Plasmids
The 463 mHes1 Luc reporter plasmid has been described previously (Take-
bayashi et al., 1994). The 414 mHes1 Luc and GR wt, GR dim, and GR D4x
expression vectors were generated by PCR-based mutagenesis and cloned
into pGL3 (Promega, Mannheim, Germany) or pcDNA3.1 (Invitrogen, Karls-
ruhe, Germany) backbone vectors using standard protocols.
Cell Culture and Transient Transfection Assays
H4IIE hepatocytes and HEK293 cells were transfected using Superfect
(QIAGEN, Hilden, Germany) reagent according to the manufacturer’s instruc-
tions. Cell extracts were prepared 48 hr after transfection, and luciferase as-
says were performed as described (Herzig et al., 2001), normalizing to the ac-
tivity from cotransfected b-galactosidase expression plasmid. Primary mouse
hepatocytes were isolated and cultured as described (Klingmu¨ller et al., 2006).
Briefly, male 8- to 12-week-old C57Bl6 were anesthetized by intraperitoneal
injection of 5 mg/100 mg body weight ketamine hydrochloride 10% and 1
mg/100 mg body weight xylazine hydrochloride 2%. After opening the abdom-
inal cavity, the liver was perfused at 37C with HANKS I (8 g NaCl, 0.4 g KCl,
3.57 g HEPES, 0.06 g Na2HPO4 3 2 H2O, 0.06 g KH2PO4 in 1 l distilled H2O,
2.5 mM EGTA, 0.1% glucose, adjusted pH to 7.4) via the portal vein for 5 min-
utes and subsequently for 5–7 min with HANKS II (8 g NaCl, 0.4 g KCl, 3.57 g
HEPES, 0.06 g Na2HPO43 2 H2O, 0.06 g KH2PO4 in 1 l distilled H2O, 0.1% glu-
cose, 3 mg/ml collagenase CLSII, 5 mM CaCl2, adjusted pH to 7.4) until disin-
tegration of the liver structure was observed. The liver capsule was removed,
and the cell suspension was filtered through a 100 mM mesh. Cells were
washed and, subsequently, viability of cells was determined by trypan blue
staining. One million living cells/well were seeded on collagen I-coated 6-
well plates. After 24 hr, cells were infected with recombinant adenoviruses
at a multiplicity of infection of 100 and harvested after an additional 48 hr.
Avidin Biotin Conjugate DNA (ABCD) Precipitation Assay
H4IIE cells were grown to 90% confluence and treated with DEX (10 nM) for
18 hr, and ABCD assays were performed as described (Herzig et al., 2003).
Consensus GRE and random oligo were used as positive and negative con-
trols, respectively. Bound GR protein was detected by western blot using
GR-specific antibody.
Statistical Analysis
Statistical analyses were performed using a 2-way analysis of variance
(ANOVA) with Bonferroni-adjusted posttests, or t test in one-factorial designs,
respectively. The significance level was at p = 0.05.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and can be found online at http://
www.cellmetabolism.org/cgi/content/full/8/3/212/DC1/.
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